TauTona Group, a privately held medical device incubator and investor, Wednesday announced that the TauTona Tissue Injector or TTI, a single-use, hand-held adipose tissue transfer tool, has received 510(k) clearance from the U.S. Food and Drug Administration or FDA.
The company also announced that it has received a key U.S. Patent for TTI from the U.S. Patent and Trademark Office and that it has other patents pending for the tool.
TTI is the second tool to emerge from the firm. Earlier this year, TauTona sold its Surgical Marker technology to Novadaq Technologies Inc., (NVDQ, NDQ.TO)
The company noted that fat grafting, in which a patient's adipose tissue is moved from one area of the body to another, is a frequently used technique that is growing in popularity for both aesthetic and reconstructive procedures.
The TTI is a battery powered, single-use tool that requires no capital investment. It is designed to deliver adipose tissue at an even, controlled rate -- with the aim of reducing the tedium and complexity of performing injections -- allowing the surgeon to focus on placement of the fat.
The device manages the pressure and flow rates during injection and is able to efficiently deliver this non-homogenous material without clogging.
Geoffrey Gurtner, managing partner at TauTona, said, "Syringes often clog and can lead to difficulty in tissue transfer procedures. The TauTona Tissue Injector is designed to help physicians simplify their fat grafting procedures, which may lead to reduced costs. We designed TTI with the aim of providing clinicians an easy-to-use, ergonomic tool to improve the efficiency of fat transfer procedures."
For comments and feedback: editorial@rttnews.com